skip to main content

Breast Cancer — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

HardBreast CancerBreast CancerSCE Medical Oncology

A patient with HER2-positive unresectable metastatic breast cancer progresses during first-line trastuzumab, pertuzumab and a taxane. She has no symptomatic brain metastases and is suitable for further anti-HER2 therapy. What is the current NICE-recommended next treatment?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: D — Second-line trastuzumab deruxtecan under the NICE access arrangement

NICE TA862 recommends trastuzumab deruxtecan after one or more anti-HER2 treatments for unresectable or metastatic HER2-positive breast cancer under the stated access arrangements. It displaced T-DM1 as the preferred second-line option after first-line trastuzumab/pertuzumab/taxane. The previous key was outdated.

Reference: NICE TA862 trastuzumab deruxtecan: recommendations (Published February 2023): https://www.nice.org.uk/guidance/ta862/chapter/1-Recommendations